Baxter Q1 2026 GAAP loss of $0.03 per share; adjusted EPS falls 35% to $0.36
Baxter reported first-quarter 2026 sales of $2.7 billion, up 3% on a reported basis but down 1% on an organic basis. The company posted a U.S. GAAP loss from continuing operations of $17 million, or $0.03 per diluted share, compared with income of $64 million a year earlier, and its adjusted diluted EPS fell 35% to $0.36. Shareholders face weaker profit even as the company reiterated its full-year 2026 outlook and declared a $0.01 quarterly dividend.
Key points
- Sales from continuing operations were $2.7 billion, up 3% reported and down 1% organic; U.S. sales fell 4% to about $1.44 billion.
- U.S. GAAP loss from continuing operations was $17 million, or $0.03 per diluted share, versus income of $64 million in the prior-year quarter.
- Adjusted diluted EPS from continuing operations was $0.36, down 35% from $0.55, with management citing tariffs, higher manufacturing costs and a prior-year timing benefit.
- Full-year 2026 adjusted EPS outlook of $1.85 to $2.05 was reiterated; the Board declared a $0.01 dividend payable July 1, 2026, to holders of record May 29, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.